Breast cancer stem cell markers CD44 and ALDH1A1 in serum: Distribution and prognostic value in patients with primary breast cancer

Yanan Kong, Ning Lyu, Jiali Wu, Hailin Tang, Xinhua Xie, Lu Yang, Xing Li, Weidong Wei, Xiaoming Xie

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: CD44 and ALDH1 have been recognized as the most widely used markers to identify breast cancer stem cells (BCSCs). However, limited to tissue sample and rare population, BCSCs have always been not easily detected. We aimed to measure CD44 and ALDH1A1 (major contributor to ALDH1 activity) levels in serum and explore the prognostic value in primary breast cancer patients. Methods: This study included 140 primary breast cancer patients with stage I-III. Serum samples were collected before surgery and stored at -80 degrees. CD44 and ALDH1A1 were measured by chemiluminescent assay. Results: High serum CD44 levels (≥ 417.4 ng/mL) were correlated with postmenopausal status (P = 0.006), estrogen receptor negativity (P = 0.025), progesterone receptor negativity (P = 0.002) and adjuvant chemotherapy (P = 0.003). The mean serum CD44 levels of luminal group (406.4 ± 68.3 ng/mL) were significantly lower than triple negative group (506.8 ± 175.5 ng/mL) (P < 0.001). There was no correlation between serum ALDH1A1 levels and molecular subtypes. Multivariate analysis revealed that high serum CD44 level (≥ 417.4 ng/mL), was an independent factor for PFS (P = 0.019) and OS (P = 0.008). However, serum ALDH1A1 has no impact on either PFS (P = 0.613) or OS (P = 0.441). Conclusion: Serum CD44 was an independent prognostic indicator in primary breast cancer. However, serum ALDH1A1 has no impact on survivals and might not be an appropriate candidate to predict prognosis for breast cancer.

Original languageEnglish (US)
Pages (from-to)3728-3735
Number of pages8
JournalJournal of Cancer
Volume9
Issue number20
DOIs
StatePublished - Jan 1 2018

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Serum
Luminescent Measurements
Progesterone Receptors
Adjuvant Chemotherapy
Estrogen Receptors
Multivariate Analysis
Survival

Keywords

  • ALDH1A1
  • Breast cancer
  • CD44
  • Prognosis
  • Stem cells

ASJC Scopus subject areas

  • Oncology

Cite this

Breast cancer stem cell markers CD44 and ALDH1A1 in serum : Distribution and prognostic value in patients with primary breast cancer. / Kong, Yanan; Lyu, Ning; Wu, Jiali; Tang, Hailin; Xie, Xinhua; Yang, Lu; Li, Xing; Wei, Weidong; Xie, Xiaoming.

In: Journal of Cancer, Vol. 9, No. 20, 01.01.2018, p. 3728-3735.

Research output: Contribution to journalArticle

Kong, Yanan ; Lyu, Ning ; Wu, Jiali ; Tang, Hailin ; Xie, Xinhua ; Yang, Lu ; Li, Xing ; Wei, Weidong ; Xie, Xiaoming. / Breast cancer stem cell markers CD44 and ALDH1A1 in serum : Distribution and prognostic value in patients with primary breast cancer. In: Journal of Cancer. 2018 ; Vol. 9, No. 20. pp. 3728-3735.
@article{c05522f9bb4a49f6afce2aaf0599f870,
title = "Breast cancer stem cell markers CD44 and ALDH1A1 in serum: Distribution and prognostic value in patients with primary breast cancer",
abstract = "Background: CD44 and ALDH1 have been recognized as the most widely used markers to identify breast cancer stem cells (BCSCs). However, limited to tissue sample and rare population, BCSCs have always been not easily detected. We aimed to measure CD44 and ALDH1A1 (major contributor to ALDH1 activity) levels in serum and explore the prognostic value in primary breast cancer patients. Methods: This study included 140 primary breast cancer patients with stage I-III. Serum samples were collected before surgery and stored at -80 degrees. CD44 and ALDH1A1 were measured by chemiluminescent assay. Results: High serum CD44 levels (≥ 417.4 ng/mL) were correlated with postmenopausal status (P = 0.006), estrogen receptor negativity (P = 0.025), progesterone receptor negativity (P = 0.002) and adjuvant chemotherapy (P = 0.003). The mean serum CD44 levels of luminal group (406.4 ± 68.3 ng/mL) were significantly lower than triple negative group (506.8 ± 175.5 ng/mL) (P < 0.001). There was no correlation between serum ALDH1A1 levels and molecular subtypes. Multivariate analysis revealed that high serum CD44 level (≥ 417.4 ng/mL), was an independent factor for PFS (P = 0.019) and OS (P = 0.008). However, serum ALDH1A1 has no impact on either PFS (P = 0.613) or OS (P = 0.441). Conclusion: Serum CD44 was an independent prognostic indicator in primary breast cancer. However, serum ALDH1A1 has no impact on survivals and might not be an appropriate candidate to predict prognosis for breast cancer.",
keywords = "ALDH1A1, Breast cancer, CD44, Prognosis, Stem cells",
author = "Yanan Kong and Ning Lyu and Jiali Wu and Hailin Tang and Xinhua Xie and Lu Yang and Xing Li and Weidong Wei and Xiaoming Xie",
year = "2018",
month = "1",
day = "1",
doi = "10.7150/jca.28032",
language = "English (US)",
volume = "9",
pages = "3728--3735",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "20",

}

TY - JOUR

T1 - Breast cancer stem cell markers CD44 and ALDH1A1 in serum

T2 - Distribution and prognostic value in patients with primary breast cancer

AU - Kong, Yanan

AU - Lyu, Ning

AU - Wu, Jiali

AU - Tang, Hailin

AU - Xie, Xinhua

AU - Yang, Lu

AU - Li, Xing

AU - Wei, Weidong

AU - Xie, Xiaoming

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: CD44 and ALDH1 have been recognized as the most widely used markers to identify breast cancer stem cells (BCSCs). However, limited to tissue sample and rare population, BCSCs have always been not easily detected. We aimed to measure CD44 and ALDH1A1 (major contributor to ALDH1 activity) levels in serum and explore the prognostic value in primary breast cancer patients. Methods: This study included 140 primary breast cancer patients with stage I-III. Serum samples were collected before surgery and stored at -80 degrees. CD44 and ALDH1A1 were measured by chemiluminescent assay. Results: High serum CD44 levels (≥ 417.4 ng/mL) were correlated with postmenopausal status (P = 0.006), estrogen receptor negativity (P = 0.025), progesterone receptor negativity (P = 0.002) and adjuvant chemotherapy (P = 0.003). The mean serum CD44 levels of luminal group (406.4 ± 68.3 ng/mL) were significantly lower than triple negative group (506.8 ± 175.5 ng/mL) (P < 0.001). There was no correlation between serum ALDH1A1 levels and molecular subtypes. Multivariate analysis revealed that high serum CD44 level (≥ 417.4 ng/mL), was an independent factor for PFS (P = 0.019) and OS (P = 0.008). However, serum ALDH1A1 has no impact on either PFS (P = 0.613) or OS (P = 0.441). Conclusion: Serum CD44 was an independent prognostic indicator in primary breast cancer. However, serum ALDH1A1 has no impact on survivals and might not be an appropriate candidate to predict prognosis for breast cancer.

AB - Background: CD44 and ALDH1 have been recognized as the most widely used markers to identify breast cancer stem cells (BCSCs). However, limited to tissue sample and rare population, BCSCs have always been not easily detected. We aimed to measure CD44 and ALDH1A1 (major contributor to ALDH1 activity) levels in serum and explore the prognostic value in primary breast cancer patients. Methods: This study included 140 primary breast cancer patients with stage I-III. Serum samples were collected before surgery and stored at -80 degrees. CD44 and ALDH1A1 were measured by chemiluminescent assay. Results: High serum CD44 levels (≥ 417.4 ng/mL) were correlated with postmenopausal status (P = 0.006), estrogen receptor negativity (P = 0.025), progesterone receptor negativity (P = 0.002) and adjuvant chemotherapy (P = 0.003). The mean serum CD44 levels of luminal group (406.4 ± 68.3 ng/mL) were significantly lower than triple negative group (506.8 ± 175.5 ng/mL) (P < 0.001). There was no correlation between serum ALDH1A1 levels and molecular subtypes. Multivariate analysis revealed that high serum CD44 level (≥ 417.4 ng/mL), was an independent factor for PFS (P = 0.019) and OS (P = 0.008). However, serum ALDH1A1 has no impact on either PFS (P = 0.613) or OS (P = 0.441). Conclusion: Serum CD44 was an independent prognostic indicator in primary breast cancer. However, serum ALDH1A1 has no impact on survivals and might not be an appropriate candidate to predict prognosis for breast cancer.

KW - ALDH1A1

KW - Breast cancer

KW - CD44

KW - Prognosis

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=85053048818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053048818&partnerID=8YFLogxK

U2 - 10.7150/jca.28032

DO - 10.7150/jca.28032

M3 - Article

AN - SCOPUS:85053048818

VL - 9

SP - 3728

EP - 3735

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 20

ER -